From Wikipedia, the free encyclopedia
Investigational selective androgen receptor modulator
S-23
|
|
Legal status |
|
---|
|
(2S)-N-(4-cyano-3-trifluoromethylphenyl)-3-(3-fluoro-4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide
|
CAS Number | |
---|
PubChem
CID | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
|
Formula | C18H13ClF4N2O3 |
---|
Molar mass | 416.76 g·mol−1 |
---|
3D model (
JSmol) | |
---|
C[C@](COC1=CC(=C(C=C1)Cl)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
|
InChI=1S/C18H13ClF4N2O3/c1-17(27,9-28-12-4-5-14(19)15(20)7-12)16(26)25-11-3-2-10(8-24)13(6-11)18(21,22)23/h2-7,27H,9H2,1H3,(H,25,26)/t17-/m0/s1 NKey:SSFVOEAXHZGTRJ-KRWDZBQOSA-N N
|
NY
(what is this?)
(verify) |
S-23 is an investigational
selective androgen receptor modulator (SARM) developed by
GTX, Inc as a potential
male hormonal contraceptive. It binds to the
androgen receptor more strongly than older drugs such as
andarine with a
Ki of 1.7 nM, and in animal studies it showed both a good ratio of
anabolic to
androgenic effects, and dose-dependent suppression of
spermatogenesis with spontaneous recovery after cessation of treatment.
[1]
[2]
References
-
^ Marhefka CA, Gao W, Chung K, Kim J, He Y, Yin D, et al. (February 2004).
"Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators". Journal of Medicinal Chemistry. 47 (4): 993–8.
doi:
10.1021/jm030336u.
PMC
2040239.
PMID
14761201.
-
^ Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT (January 2009).
"Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception". Endocrinology. 150 (1): 385–95.
doi:
10.1210/en.2008-0674.
PMC
2630904.
PMID
18772237.
|
---|
ARTooltip Androgen receptor | Agonists | |
---|
SARMsTooltip Selective androgen receptor modulator | |
---|
Antagonists | |
---|
|
---|
GPRC6A | |
---|
|